The FDA has approved a regimen for treating metastatic castration-sensitive prostate cancer in patients with a BRCA2 mutation. The approved treatment combines niraparib with abiraterone acetate and prednisone. Reports indicate this approval provides a new option for patients with BRCA2-positive advanced prostate cancer, although details of the approval's scope and implications are still emerging.